Works matching AU Yang, Guangjian

Results: 35

Thoracic epithelioid inflammatory myofibroblastic sarcoma: a rare and aggressive disease with case report and literature review.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01375-5

By:

Yang, Linke;
Li, Pei;
Liu, Runze;
Feng, Baomin;
Mao, Huiqing;
Tang, Xiaoyong;
Yang, Guangjian

Publication type:

Article

Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01154-2

By:

Yang, Guangjian;
Liu, Runze;
Li, Pei;
Yang, Yaning;
Wang, Yajie;
Mao, Huiqing;
Tang, Xiaoyong

Publication type:

Article

Long-term disease free survival of gastric mixed adenoneuroendocrine carcinoma treated with multimodality therapy: A case report.

Published in:

2018

By:

Yang, Guangjian;
Li, Dan;
Zheng, Fangchao;
Yang, Lin

Publication type:

Case Study

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.

Published in:

2020

By:

Xu, Haiyan;
Li, Weihua;
Yang, Guangjian;
Li, Junling;
Yang, Lu;
Xu, Fei;
Yang, Yaning;
Ying, Jianming;
Wang, Yan

Publication type:

journal article

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).

Published in:

BMC Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12916-022-02470-6

By:

Yang, Guangjian;
Xu, Haiyan;
Yang, Yaning;
Zhang, Shuyang;
Xu, Fei;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan;
Hu, Xingsheng;
Liu, Yutao;
Wang, Lin;
Lin, Lin;
Wang, Zhijie;
Duan, Jianchun;
Wang, Jie;
Wang, Yan

Publication type:

Article

Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-01749-3

By:

Yang, Guangjian;
Tian, Linyan;
Wang, Yan

Publication type:

Article

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study.

Published in:

Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221082339

By:

Yang, Guangjian;
Yang, Yaning;
Liu, Runze;
Li, Weihua;
Xu, Haiyan;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan;
Zhang, Shuyang;
Ai, Xin;
Xu, Fei;
Wang, Yan

Publication type:

Article

Structure-Function Analysis of the Transmembrane Protein AmpG from Pseudomonas aeruginosa.

Published in:

PLoS ONE, 2016, v. 11, n. 12, p. 1, doi. 10.1371/journal.pone.0168060

By:

Li, Peizhen;
Ying, Jun;
Yang, Guangjian;
Li, Aifang;
Wang, Jian;
Lu, Junwan;
Wang, Junrong;
Xu, Teng;
Yi, Huiguang;
Li, Kewei;
Jin, Shouguang;
Bao, Qiyu;
Zhang, Kaibo

Publication type:

Article

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.984503

By:

Guangjian Yang;
Yaning Yang;
Jiaqi Hu;
Haiyan Xu;
Shuyang Zhang;
Yan Wang

Publication type:

Article

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.976731

By:

Haiyan Xu;
Guangjian Yang;
Runze Liu;
Yaning Yang;
Weihua Li;
Junling Li;
Xuezhi Hao;
Puyuan Xing;
Yan Wang

Publication type:

Article

Pulmonary NUT carcinoma, an elusive and refractory entity, shows transient response to chemotherapeutics and PD-1 inhibitor: a case report and literature review.

Published in:

2025

By:

Yang, Guangjian;
Liu, Runze;
Yang, Linke;
Yang, Xue;
Tang, Xiaoyong;
Mao, Huiqing

Publication type:

Case Study

The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study.

Published in:

Cancer Medicine, 2023, v. 12, n. 19, p. 19438, doi. 10.1002/cam4.6545

By:

Zhang, Shuyang;
Yang, Lu;
Yang, Yaning;
Yang, Guangjian;
Xu, Haiyan;
Niu, Xueliang;
Wang, Yan

Publication type:

Article

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China.

Published in:

Cancer Medicine, 2023, v. 12, n. 1, p. 335, doi. 10.1002/cam4.4852

By:

Yang, Guangjian;
Yang, Yaning;
Liu, Runze;
Li, Weihua;
Xu, Haiyan;
Hao, Xuezhi;
Li, Junling;
Zhang, Shuyang;
Xu, Fei;
Lei, Siyu;
Wang, Yan

Publication type:

Article

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients.

Published in:

Cancer Medicine, 2021, v. 10, n. 23, p. 8328, doi. 10.1002/cam4.4336

By:

Yang, Yaning;
Xu, Haiyan;
Ma, Li;
Yang, Lu;
Yang, Guangjian;
Zhang, Shuyang;
Ai, Xin;
Zhang, Shucai;
Wang, Yan

Publication type:

Article

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants.

Published in:

Cancer Medicine, 2020, v. 9, n. 10, p. 3328, doi. 10.1002/cam4.2984

By:

Xu, Haiyan;
Zhang, Quan;
Liang, Li;
Li, Junling;
Liu, Zhefeng;
Li, Weihua;
Yang, Lu;
Yang, Guangjian;
Xu, Fei;
Ying, Jianming;
Zhang, Shucai;
Wang, Yan

Publication type:

Article

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study.

Published in:

Cancer Medicine, 2019, v. 8, n. 13, p. 5823, doi. 10.1002/cam4.2420

By:

Yang, Guangjian;
Ma, Di;
Xu, Haiyan;
Yang, Lu;
Li, Junling;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Yan

Publication type:

Article

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer.

Published in:

Cancer Medicine, 2019, v. 8, n. 4, p. 1551, doi. 10.1002/cam4.2043

By:

Song, Peng;
Zhang, Fanshuang;
Li, Yan;
Yang, Guangjian;
Li, Wenbin;
Ying, Jianming;
Gao, Shugeng

Publication type:

Article

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2 -Targeted Tyrosine Kinase Inhibitors.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.806737

By:

Yang, Guangjian;
Xu, Haiyan;
Hu, Jiaqi;
Liu, Runze;
Hu, Peizeng;
Yang, Yaning;
Li, Weihua;
Hao, Xuezhi;
Zhang, Shuyang;
Xu, Fei;
Ai, Xin;
Li, Junling;
Wang, Yan

Publication type:

Article

Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery.

Published in:

Cancer Management & Research, 2020, v. 12, p. 12549, doi. 10.2147/CMAR.S286503

By:

Yang, Lu;
Pang, Chong;
Xu, Fei;
Yang, Guangjian;
Xu, Haiyan;
Wang, Changli;
Wang, Yan

Publication type:

Article

Effects of phycoerythrin from Gracilaria lemaneiformis in proliferation and apoptosis of SW480 cells.

Published in:

Oncology Reports, 2016, v. 36, n. 6, p. 3536, doi. 10.3892/or.2016.5162

By:

PEIZHEN LI;
JUN YING;
QINGLI CHANG;
WEN ZHU;
GUANGJIAN YANG;
TENG XU;
HUIGUANG YI;
RUOWANG PAN;
ENYONG ZHANG;
XIAOFENG ZENG;
CHUNXIA YAN;
QIYU BAO;
SHENGBIN LI

Publication type:

Article

Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.

Published in:

BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12228-3

By:

Yin, Xiaoyan;
Zhu, Wanqi;
Tang, Xiaoyong;
Yang, Guangjian;
Zhao, Xianguang;
Zhao, Kaikai;
Jiang, Liyang;
Li, Xiaolin;
Zhao, Hong;
Wang, Xin;
Yan, Yuanyuan;
Xing, Ligang;
Yu, Jinming;
Meng, Xiangjiao;
Zhao, Hanxi

Publication type:

Article

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice.

Published in:

Thoracic Cancer, 2022, v. 13, n. 23, p. 3295, doi. 10.1111/1759-7714.14684

By:

Yang, Yaning;
Ai, Xin;
Xu, Haiyan;
Yang, Guangjian;
Yang, Lu;
Hao, Xuezhi;
Yang, Ke;
Mi, Yuling;
Wang, Guizhen;
Zhang, Shuyang;
Lei, Siyu;
Wang, Yan

Publication type:

Article

Novel genetic characteristics in low‐grade fetal adenocarcinoma of the lung.

Published in:

Thoracic Cancer, 2021, v. 12, n. 20, p. 2789, doi. 10.1111/1759-7714.14126

By:

Zhang, Shuyang;
Yin, Huihui;
Zhang, Jing;
Yang, Lu;
Yang, Guangjian;
Jia, Jia;
Jiao, Yuchen;
Ying, Jianming;
Wang, Yan

Publication type:

Article

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs.

Published in:

Thoracic Cancer, 2020, v. 11, n. 12, p. 3501, doi. 10.1111/1759-7714.13689

By:

Yang, Lu;
Hao, Xuezhi;
Hu, Xingsheng;
Wang, Zhijie;
Yang, Ke;
Mi, Yuling;
Yang, Yaning;
Xu, Haiyan;
Yang, Guangjian;
Wang, Yan

Publication type:

Article

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China.

Published in:

Thoracic Cancer, 2020, v. 11, n. 3, p. 679, doi. 10.1111/1759-7714.13317

By:

Xu, Fei;
Yang, Guangjian;
Xu, Haiyan;
Yang, Lu;
Qiu, Weini;
Wang, Yan

Publication type:

Article

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance.

Published in:

Thoracic Cancer, 2019, v. 10, n. 5, p. 1096, doi. 10.1111/1759-7714.13050

By:

Xu, Haiyan;
Yang, Guangjian;
Yang, Lu;
Yang, Yaning;
Ma, Di;
Li, Junling;
Hao, Xuezhi;
Xing, Puyuan;
Wang, Yan

Publication type:

Article

Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis.

Published in:

2020

By:

Yang, Guangjian;
Yin, Jiangxia;
Ou, Kai;
Du, Qiang;
Ren, Wenhao;
Jin, Yujing;
Peng, Liming;
Yang, Lin

Publication type:

journal article

The value of blood biomarkers of progression and prognosis in ALK‐positive patients with non–small cell lung cancer treated with crizotinib.

Published in:

Asia Pacific Journal of Clinical Oncology, 2020, v. 16, n. 1, p. 63, doi. 10.1111/ajco.13284

By:

Yang, Yaning;
Xu, Haiyan;
Yang, Guangjian;
Yang, Lu;
Li, Junling;
Wang, Yan

Publication type:

Article

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-00899-0

By:

Li, Pei;
Ju, Xiao;
Yang, Guangjian

Publication type:

Article

SuhB Regulates the Motile-Sessile Switch in Pseudomonas aeruginosa through the Gac/Rsm Pathway and c-di-GMP Signaling.

Published in:

Frontiers in Microbiology, 2017, p. 1, doi. 10.3389/fmicb.2017.01045

By:

Kewei Li;
Guangjian Yang;
Debru, Alexander B.;
Pingping Li;
Li Zong;
Peizhen Li;
Teng Xu;
Weihui Wu;
Shouguang Jin;
Qiyu Bao

Publication type:

Article

Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.

Published in:

Thoracic Cancer, 2023, v. 14, n. 33, p. 3275, doi. 10.1111/1759-7714.15118

By:

Yaning Yang;
Guangjian Yang;
Weihua Li;
Xuezhi Hao;
Shuyang Zhang;
Xin Ai;
Siyu Lei;
Haiyan Xu;
Yan Wang

Publication type:

Article

The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.843299

By:

Yang, Guangjian;
Liu, Chengming;
Hu, Jiaqi;
Sun, Yang;
Hu, Peizeng;
Liu, Liu;
Xu, Haiyan;
Li, Dazhou;
Li, Weihua;
Yang, Yaning;
Sun, Nan;
He, Jie;
Wang, Yan

Publication type:

Article

A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.

Published in:

Frontiers in Oncology, 2022, v. 11, p. 1, doi. 10.3389/fonc.2021.756902

By:

Xu, Fei;
Xu, Haiyan;
Wan, Zhiyi;
Yang, Guangjian;
Yang, Lu;
Wu, Xueying;
Song, Jin;
Wang, Yan

Publication type:

Article

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes.

Published in:

Frontiers in Oncology, 2021, v. 12, p. 1, doi. 10.3389/fonc.2021.713483

By:

Xu, Haiyan;
Yang, Guangjian;
Li, Weihua;
Li, Junling;
Hao, Xuezhi;
Xing, Puyuan;
Yang, Yaning;
Wang, Yan

Publication type:

Article

Explore the Optimal Resolvent of Medical Needs and Mental Health for Patients with Lung Cancer during Epidemic Novel Coronavirus Pneumonia.

Published in:

Chinese Journal of Lung Cancer, 2020, v. 23, n. 4, p. 247, doi. 10.3779/j.issn.1009-3419.2020.101.12

By:

Haiyan XU;
Ke YANG;
Guangjian YANG;
Lu YANG;
Yuling MI;
Xiaohong CUI;
Min YANG;
Dan WANG;
Yan WANG

Publication type:

Article